Literature DB >> 7937278

Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug.

C A Peloquin1, G T James, L D Craig, M Kim, E A McCarthy, D Iklé, M D Iseman.   

Abstract

STUDY
OBJECTIVE: To determine the bioavailability and renal elimination of isoniazid, acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, aconiazide, and 2-formylphenoxyacetic acid. STUDY
DESIGN: Randomized, double-blind, two-period, crossover phase I study.
SETTING: Pharmacokinetics unit at a referral hospital that specializes in the treatment of mycobacterial infections.
SUBJECTS: Twelve healthy volunteers selected from the hospital staff.
INTERVENTIONS: Subjects received aconiazide tablets 650 mg (containing isoniazid 300 mg) and isoniazid tablets 300 mg. Blood and urine samples were collected over 24 hours after the dose.
MEASUREMENTS AND MAIN RESULTS: Intact aconiazide and 2-formylphenoxyacetic acid were not detected in the serum. Compared with isoniazid tablets, aconiazide's relative bioavailability (based on the area under the serum concentration-time curve) was 50.7%; its relative maximum serum concentration was 13.4%.
CONCLUSIONS: Isoniazid is less bioavailable after aconiazide tablets than after isoniazid tablets. The optimum dose of aconiazide remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937278

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

2.  New anti-tuberculosis agents amongst known drugs.

Authors:  Kathryn E A Lougheed; Debra L Taylor; Simon A Osborne; Justin S Bryans; Roger S Buxton
Journal:  Tuberculosis (Edinb)       Date:  2009-08-20       Impact factor: 3.131

3.  Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions.

Authors:  Tino Wilson Sanchez; Bikash Debnath; Frauke Christ; Hiroyuki Otake; Zeger Debyser; Nouri Neamati
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

Review 4.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.